Advertisement

Vascular Endothelial Growth Factor as a Determinant of Diabetic Nephropathy

  • Geoffrey Boner
  • Mark E. Cooper
Part of the Contemporary Diabetes book series (CDI)

Abstract

Diabetic nephropathy is the major cause of end-stage renal disease in the United States and in many other countries (1, 2, 3). The development of diabetic nephropathy is thought to occur as a result of an interplay between hemodynamic and metabolic factors (4,5). The various metabolic factors, such as the renal accumulation of advanced glycation end (AGE) products and activation of the polyol pathway, as well as hemodynamic changes, including changes in vasoactive hormones such as the renin-angiotensin system (RAS), act through the stimulation of various intracellular second messengers, cytokines and growth factors to induce end-organ injury (5,6). Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor because of its ability to stimulate vascular permeability, was later shown to have a mitogenic effect in endothelial cells (7,8). Indeed, VEGF was shown to stimulate angiogenesis (8) and has subsequently been postulated to play a role in the pathogenesis of various complications of diabetes (9). In this chapter, we will discuss the role of VEGF, as yet not fully delineated in the development of diabetic nephropathy.

Keywords

Vascular Endothelial Growth Factor Diabetic Nephropathy Vascular Endothelial Growth Factor Expression Vascular Endothelial Growth Factor Level Vascular Endothelial Growth Factor mRNA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    US Renal Data System: Excerpts from the USRDS 2004 Annual Data Report. Am J Kidney Dis 2005;45(1):S57–S70.Google Scholar
  2. 2.
    US Renal Data System: Excerpts from the USRDS 2001 Annual Data Report. Am J Kidney Dis 2001;38(3):S195–S200.Google Scholar
  3. 3.
    Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type-2 diabetes; A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795–808.PubMedGoogle Scholar
  4. 4.
    Cooper ME, Gilbert RE, Epstein M. Pathophysiology of Diabetic Nephropathy. Metabolism 1998;47:3–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001;44:1957–1972.PubMedCrossRefGoogle Scholar
  6. 6.
    Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocrine Rev 2004;25:971–1010.CrossRefGoogle Scholar
  7. 7.
    Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9–22.PubMedGoogle Scholar
  8. 8.
    Ferrara N, Gerber H-P. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001;106:148–156.PubMedCrossRefGoogle Scholar
  9. 9.
    Khamaisi M, Schrijvers BF, De Vriese AS, Raz I, Flyvbjerg A. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 2003;18:1427–1430.PubMedCrossRefGoogle Scholar
  10. 10.
    Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004;65:2003–2017.PubMedCrossRefGoogle Scholar
  11. 11.
    Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439–442.PubMedCrossRefGoogle Scholar
  12. 12.
    Galiano RD, Tepper OM, Pelo CR, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004;164:1935–1947.PubMedGoogle Scholar
  13. 13.
    Gilbert RE, Vranes D, Berka JL, et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 1998;78:1017–1027.PubMedGoogle Scholar
  14. 14.
    Zhang X, Lassila M, Cooper ME, Cao Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension 2004;43:276–281.PubMedCrossRefGoogle Scholar
  15. 15.
    Cukiernik M, Hileeto D, Evans T, Mukherjee S, Downey D, Chakrabarti S. Vascular endothelial growth factor in diabetes induced early retinal abnormalities. Diabetes Res Clin Pract 2004;65:197–208.PubMedCrossRefGoogle Scholar
  16. 16.
    Nicoletti VG, Nicoletti R, Ferrara N, Meli G, Reibaldi M, Reibaldi A. Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). Exp Clin Endocrinol Diabetes 2003;111:209–214.PubMedCrossRefGoogle Scholar
  17. 17.
    Itakura H, Kishi S, Kotajima N, Murakami M. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. Ophthalmology 2004;111:1880–1884.PubMedCrossRefGoogle Scholar
  18. 18.
    Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442–455.PubMedCrossRefGoogle Scholar
  19. 19.
    Simon M, Grone HJ, Johren O, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995;268:F240–F250.PubMedGoogle Scholar
  20. 20.
    Brown LF, Berse B, Tognazzi K, et al. Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int 1992;42:1457–1461.PubMedCrossRefGoogle Scholar
  21. 21.
    Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999;48:2229–2239.PubMedCrossRefGoogle Scholar
  22. 22.
    Simon M, Rockl W, Hornig C, et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. J Am Soc Nephrol 1998;9:1032–1044.PubMedGoogle Scholar
  23. 23.
    Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003;111:707–716.PubMedCrossRefGoogle Scholar
  24. 24.
    Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995;25:913–917.PubMedGoogle Scholar
  25. 25.
    Pupilli C, Lasagni L, Romagnani P, et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 1999;10:245–255.PubMedCrossRefGoogle Scholar
  26. 26.
    Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996;7:661–666.PubMedGoogle Scholar
  27. 27.
    Boner G, Cox AJ, Kelly DJ, et al. Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease? Nephrol Dial Transplant 2003;18:2293–2299.PubMedCrossRefGoogle Scholar
  28. 28.
    Remuzzi G, Benigni A. Repairing renal lesions: will VEGF be the builder? Kidney Int 2000;58:2594–2595.PubMedCrossRefGoogle Scholar
  29. 29.
    Braun L, Kardon T, Reisz-Porszasz ZS, Banhegyi G, Mandl J. The regulation of the induction of vascular endothelial growth factor at the onset of diabetes in spontaneously diabetic rats. Life Sci 2001;69:2533–2542.PubMedCrossRefGoogle Scholar
  30. 30.
    Cha DR, Kang YS, Han SY, et al. Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J Endocrinol 2004;183:183–194.PubMedCrossRefGoogle Scholar
  31. 31.
    Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999;42:579–588.PubMedCrossRefGoogle Scholar
  32. 32.
    Hoshi S, Shu Y, Yoshida F, et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest 2002;82:25–35.PubMedGoogle Scholar
  33. 33.
    de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993–1000.PubMedGoogle Scholar
  34. 34.
    Schrijvers BF, Rasch R, Tilton RG, Flyvbjerg A. High protein-induced glomerular hypertrophy is vascular endothelial growth factor-dependent. Kidney Int 2002;61:1600–1604.PubMedCrossRefGoogle Scholar
  35. 35.
    Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type-2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002;51:3090–3094.PubMedCrossRefGoogle Scholar
  36. 36.
    Kakizawa H, Itoh Y, Imamura S, et al. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist. Horm Metab Res 2004;36:458–464.PubMedCrossRefGoogle Scholar
  37. 37.
    Sato T, Murao M, Kumal T, et al. Hemodynamic mechanisms involved in the early stage of diabetic nephropathy in the Wistar fatty rats, a model of type-2 diabetes: Roles of renal NO metabolisms and VEGF. Abstract 2693, American Society of Nephrology, Renal Week, St Louis, October 2004.Google Scholar
  38. 38.
    Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclo-oxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002;62:929–939.PubMedCrossRefGoogle Scholar
  39. 39.
    Qin J, Zhang Z, Liu J, et al. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 2003;64:565–571.PubMedCrossRefGoogle Scholar
  40. 40.
    Thallas-Bonke V, Lindschau C, Rizkalla B, et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004;53:2921–2930.PubMedCrossRefGoogle Scholar
  41. 41.
    Menne J, Park JK, Boehne M, et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes 2004;53:2101–2109.PubMedCrossRefGoogle Scholar
  42. 42.
    Rizkalla B, Forbes JM, Cao Z, Boner G, Cooper ME. Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system. J Hypertens 2005;23:153–164.PubMedCrossRefGoogle Scholar
  43. 43.
    Rizkalla B, Forbes JM, Cooper ME, Cao Z. Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 2003;14:3061–3071.PubMedCrossRefGoogle Scholar
  44. 44.
    Zhang X, Lassila M, Cooper ME, Cao Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension 2004;43:276–281.PubMedCrossRefGoogle Scholar
  45. 45.
    Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 2003;163:879–887.PubMedGoogle Scholar
  46. 46.
    Cha DR, Kim NH, Yoon JW, et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 2000;77:S104–S112.PubMedCrossRefGoogle Scholar
  47. 47.
    Kim NH, Jung HH, Cha DR, Choi DS. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. J Endocrinol 2000;165:617–624.PubMedCrossRefGoogle Scholar
  48. 48.
    El Awad B, Kreft B, Wolber EM, et al. Hypoxia and interleukin-1beta stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int 2000;58:43–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Gruden G, Thomas S, Burt D, et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999;10:730–737.PubMedGoogle Scholar
  50. 50.
    Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, et al. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002;62:901–913.CrossRefGoogle Scholar
  51. 51.
    Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN. Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-beta1 in mouse podocytes. Diabetes 2004;53:2939–2949.PubMedCrossRefGoogle Scholar
  52. 52.
    Chen S, Lee JS, Kasama Y, Marin M, Ziyadeh FN, Sung SH. TGF-β1 stimulation of α3(IV) collagen production in mouse podocytes is partly mediated VEGF autocrine loop involving PI3K and PKC. J Am Soc Nephrol 2004;15:31A, “;abstract.”CrossRefGoogle Scholar
  53. 53.
    Yamagishi S, Inagaki Y, Okamoto T, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002;277:20,309–20,315.PubMedCrossRefGoogle Scholar
  54. 54.
    Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factorkappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999;48:1131–1137.PubMedCrossRefGoogle Scholar
  55. 55.
    Saijonmaa O, Nyman T, Kosonen R, Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am J Physiol Heart Circ Physiol 2001;280:H885–H891.PubMedGoogle Scholar
  56. 56.
    Baba T, Osterby R, Neugebauer-Baba S, et al. No nephropathy in type-2 diabetic patient with POEMS syndrome with an elevated plasma VEGF. Diabet Med 2004;21:292–294.PubMedCrossRefGoogle Scholar
  57. 57.
    Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P.Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004;53:861–864.PubMedCrossRefGoogle Scholar
  58. 58.
    Abdel Aziz MY, Ben Gharbia O, el-Sayed Mohamed K, Muchaneta-Kubara EC, el Nahas AM. VEGF and diabetic microvascular complications. Nephrol Dial Transplant 1997;12:1538.PubMedCrossRefGoogle Scholar
  59. 59.
    Hovind P, Tarnow L, Oestergaard PB, Parving HH. Elevated vascular endothelial growth factor in type-1 diabetic patients with diabetic nephropathy. Kidney Int Suppl 2000;75:S56–S61.PubMedCrossRefGoogle Scholar
  60. 60.
    Chiarelli F, Spagnoli A, Basciani F, et al. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with type-1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 2000;17:650–656.PubMedCrossRefGoogle Scholar
  61. 61.
    Santilli F, Spagnoli A, Mohn A, et al. Increased vascular endothelial growth factor serum concentrations may help to identify patients with onset of type-1 diabetes during childhood at risk for developing persistent microalbuminuria. J Clin Endocrinol Metab 2001;86:3871–3876.PubMedCrossRefGoogle Scholar
  62. 62.
    Lenz T, Haak T, Malek J, Grone HJ, Geiger H, Gossmann J. Vascular endothelial growth factor in diabetic nephropathy. J Biol Chem 2004;279:3941–3948.Google Scholar
  63. 63.
    Kim NH, Kim KB, Kim DL, et al. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type-2 diabetes mellitus. Diabet Med 2004;21:545–551.PubMedCrossRefGoogle Scholar
  64. 64.
    Lim HS, Blann AD, Chong AY, Freestone B, Lip GY. Plasma Vascular Endothelial Growth Factor, Angiopoietin-1, and Angiopoietin-2 in Diabetes: Implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004;27:2918–2924.PubMedCrossRefGoogle Scholar
  65. 65.
    Malamitsi-Puchner A, Sarandakou A, Tziotis J, Dafogianni C, Bartsocas CS. Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type-1 diabetes mellitus. Pediatr Res 1998;44:873–875.PubMedCrossRefGoogle Scholar
  66. 66.
    Chaturvedi N, Fuller JH, Pokras F, Rottiers R, Papazoglou N, Aiello LP. EUCLID Study Group. Circulating plasma vascular endothelial growth factor and microvascular complications of type-1 diabetes mellitus: the influence of ACE inhibition. Diabet Med 2001;18:288–294.PubMedCrossRefGoogle Scholar
  67. 67.
    Shimada K, Baba T, Neugebauer S, et al. Plasma vascular endothelial growth factor in Japanese type-2 diabetic patients with and without nephropathy. J Diabetes Complications 2002;16:386–390.PubMedCrossRefGoogle Scholar
  68. 68.
    Cipriani R, Sensi M, Gabriele A, et al. The impairment of renal function is not associated to altered circulating vascular endothelial growth factor in patients with type-2 diabetes and hypertension. Diabetes Nutr Metab 2004;17:90–94.PubMedGoogle Scholar
  69. 69.
    Kim NH, Oh JH, Seo JA, et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 2005;67:167–177.PubMedCrossRefGoogle Scholar
  70. 70.
    Bortoloso E, Del Prete D, Dalla Vestra M, et al. Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type-2 diabetes. Eur J Endocrinol 2004;150:799–807.PubMedCrossRefGoogle Scholar
  71. 71.
    Bortoloso E, Del Prete D, Gambaro G, et al. Vascular endothelial growth factor (VEGF) and VEGF receptors in diabetic nephropathy: expression studies in biopsies of type-2 diabetic patients. Ren Fail 2001;23:483–493.PubMedCrossRefGoogle Scholar
  72. 72.
    Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E, Bruijn JA. Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am J Kidney Dis 2004;43:636–650.PubMedCrossRefGoogle Scholar
  73. 73.
    Kanesaki Y, Suzuki D, Uehara G, et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 2005;45:288–294.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Geoffrey Boner
    • 1
    • 2
  • Mark E. Cooper
    • 2
  1. 1.Department of Internal MedicineSackler Faculty of Medicine, Tel Aviv UniversityTel AvivIsrael
  2. 2.Danielle Alberti Memorial Centre for Diabetes Complications, Vascular Division, Wynn DomainBaker Medical Research InstituteMelbourneAustralia

Personalised recommendations